Cambridge, Mass.
Transkaryotic Therapies Inc. is building a 185,000-sf headquarters and state-of-the-art laboratory and research facility in an MIT-owned building in Cambridge. The $65 million project, developed by Barr & Barr Inc., involves renovating the existing building, including restoration of the historical building's 150-year-old facade.
